J Clay Bavinger1, Karen DeLoss, Shahzad I Mian. 1. Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: Dry eye syndrome can be difficult to manage in severe or refractory cases. In patients in whom traditional treatments have limited efficacy, alternative treatments may be considered for dry eye syndrome, including scleral lenses. The present review summarizes the evidence regarding scleral lens use in dry eye syndrome. RECENT FINDINGS: Scleral lenses have become a viable option for severe dry eye syndrome, and have been shown to be efficacious and well tolerated, with most reports citing improved visual acuity and relief of symptoms. Currently, there are 18 manufacturers of scleral lenses, although published reports on scleral lenses primarily focus on the BostonSight PROSE and the Jupiter Lens. SUMMARY: Scleral lenses are efficacious and well tolerated for use in severe dry eye syndrome. Further research is needed to compare different sizes and types of lenses, and to standardize outcome measures.
PURPOSE OF REVIEW: Dry eye syndrome can be difficult to manage in severe or refractory cases. In patients in whom traditional treatments have limited efficacy, alternative treatments may be considered for dry eye syndrome, including scleral lenses. The present review summarizes the evidence regarding scleral lens use in dry eye syndrome. RECENT FINDINGS: Scleral lenses have become a viable option for severe dry eye syndrome, and have been shown to be efficacious and well tolerated, with most reports citing improved visual acuity and relief of symptoms. Currently, there are 18 manufacturers of scleral lenses, although published reports on scleral lenses primarily focus on the BostonSight PROSE and the Jupiter Lens. SUMMARY: Scleral lenses are efficacious and well tolerated for use in severe dry eye syndrome. Further research is needed to compare different sizes and types of lenses, and to standardize outcome measures.
Authors: L Magro; J Gauthier; M Richet; M Robin; S Nguyen; F Suarez; J-H Dalle; T Fagot; A Huynh; M-T Rubio; R Oumadely; S Vigouroux; N Milpied; A Delcampe; I Yakoub-Agha Journal: Bone Marrow Transplant Date: 2017-02-20 Impact factor: 5.483
Authors: Anny M S Cheng; Dandan Zhao; Rendian Chen; Han Y Yin; Sean Tighe; Hosam Sheha; Victoria Casas; Scheffer C G Tseng Journal: Ocul Surf Date: 2015-09-24 Impact factor: 5.033